Related Experiment Videos
Interstitial pneumonia induced by ticlopidine
Ryosai Nakamura1, Takuroh Imamura, Hisamitsu Onitsuka
1First Department of Internal Medicine, Miyazaki Medical College, Kiyotake, Japan.
Summary
Ticlopidine, a platelet aggregation inhibitor, can cause interstitial pneumonia. This rare but serious side effect, characterized by lung inflammation, necessitates clinical consideration due to the drug
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Familial hypercholesterolemia and severe atherosclerosis increase cardiovascular risk.
- Platelet aggregation inhibitors like ticlopidine are used to manage atherosclerosis complications.
Observation:
- A 67-year-old female developed interstitial pneumonia after ticlopidine initiation.
- Diagnostic tests, including lymphocyte stimulation and bronchoalveolar lavage, indicated ticlopidine-induced lung injury.
- Previous cases of ticlopidine-associated pneumonia are rare but documented.
Findings:
- Ticlopidine therapy was linked to interstitial pneumonia in a patient with atherosclerosis.
- Positive lymphocyte stimulation tests and altered CD4+/8+ ratios supported drug-induced hypersensitivity.
- Pneumonia resolved after discontinuing ticlopidine and initiating corticosteroid therapy.
Implications:
- Ticlopidine can cause serious pulmonary adverse effects, including interstitial pneumonia.
- Clinicians should consider ticlopidine-induced pneumonia in patients presenting with unexplained respiratory symptoms.
- Awareness of this rare side effect is crucial given ticlopidine's widespread use.